From algae to eye‑sight: Nobel laureates pioneer light‑controlled brain therapy

On 5 October 2026, the Nobel Assembly at the Karolinska Institutet awarded the Nobel Prize in Physiology or Medicine to Karl Deisseroth, Peter Hegemann, and Georg Nagel. The committee recognized the trio for their discoveries concerning light-gated ion channels and optogenetics.

Peter Hegemann of Humboldt University in Berlin and Georg Nagel of the University of Würzburg are credited with identifying channelrhodopsin in algae. Karl Deisseroth, a professor at Stanford University and a Howard Hughes Medical Institute investigator, subsequently converted these proteins into a light-controlled neural switch.

This technology, known as optogenetics, allows researchers to switch the activity of individual nerve cells in a living brain on or off with millisecond precision. By using light to manipulate specific neurons, scientists have transformed abstract brain maps into testable circuits.

The transition from basic science to clinical application is already underway. Researchers are currently using optogenetic techniques in clinical trials to restore vision in patients with retinitis pigmentosa by inserting light-sensitive proteins into the retina. Additionally, scientists are investigating whether the technology can improve cochlear implants by providing more precise stimulation of the auditory nerve than existing electrical devices.

The Nobel recognition highlights the rapid evolution of this field. While the initial discovery relied on proteins found in algae, the resulting tool is now a global standard for mapping brain circuits and testing potential therapies for neurological and sensory disorders. The award is expected to accelerate funding and regulatory attention, potentially shortening the timeline for bringing these gene-based therapies to patients.

Future progress remains dependent on how quickly these therapies can move from animal models to approved human treatments. Questions also persist regarding the necessary ethical and safety frameworks for permanent, light-controlled modifications in the human brain, as well as the technology's scalability for treating complex psychiatric conditions like depression or PTSD.

- [nobelprize.org](https://www.nobelprize.org/prizes/medicine/2026/press-release/) - [rte.ie](https://www.rte.ie/news/world/2026/1005/1594036-german-us-scientists-nobel-prize/) - [hhmi.org](https://www.hhmi.org/news/karl-deisseroth-2026-nobel-prize-physiology-medicine) - [dongascience.com](https://www.dongascience.com/en/news/80192)